Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Bend, OR MSA — September 2026
Bend clinical pay outpaces the nation as local talent tightens.
Bend's Clinical Research Associate advertised pay hit $119,506 against a national median of $90,956, even as metro unemployment held at 4.3%, well under Oregon's 5.1% statewide rate.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Bend MSA unemployment rate: 4.3% — vs 5.1% statewide, Aug 2026
- CRA advertised pay gap: $119,506 vs $90,956 — Bend vs national median, both rising
- Bend job postings growth: +4.0% YoY — Q1 2026, bucking Oregon's statewide decline
- Lab/R&D vacancy rate: 23.2% — Top 13 U.S. life sciences markets, Q1 2026
Key takeaways
Clinical research pay in Bend is outrunning the national market.
CRA advertised pay sits roughly 31% above the national median and is still rising, a gap wide enough to suggest local clinical trial and device employers are competing against each other, not just national benchmarks. Firms anchoring offers to national survey data risk losing candidates mid-process.
Lab Technician pay is diverging from the national trend.
Bend's Lab Technician advertised pay rose moderately to $59,724 while the national figure declined to $47,402 — a reversal of direction that points to tight local entry-level lab supply even as national demand softens. Expect continued pressure on quality and manufacturing support roles that feed from the same technician pipeline.
Lonza and St. Charles anchor a tighter-than-state talent market.
Bend's sub-state unemployment rate and above-national clinical pay levels reflect concentrated demand from a small number of large life sciences and healthcare employers rather than broad-based economic strength. Smaller biotech and device firms competing against these anchors for regulatory, quality and clinical staff should expect limited local bench depth.
Validation Engineer demand signals manufacturing investment, not just backfill.
Metro pay for Validation Engineers climbed to $114,932, outpacing the national figure, consistent with sustained biologics and device manufacturing capacity build-out nationally. Rising validation and CMC-adjacent pay locally may indicate Bend employers are staffing ahead of production scale-up rather than simply replacing attrition.
Median advertised pay by role — Bend, OR MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $143,596 | $148,237 | $148,237 | Stable | $131,354 |
| Clinical Research Associate * | $67,756 | $119,506 | $128,771 | Significant increase | $90,956 |
| Lab Technician * | $45,169 | $59,724 | $69,209 | Moderate increase | $47,402 |
| Regulatory Affairs Specialist * | $89,000 | $110,343 | $118,621 | Significant increase | $104,000 |
| Clinical Data Manager * | $124,704 | $142,800 | $145,083 | Significant increase | $123,031 |
| Biostatistician * | $109,447 | $168,864 | $170,803 | Significant increase | $133,322 |
| Validation Engineer | $96,927 | $114,932 | $126,500 | Moderate increase | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Bend MSA unemployment held at 4.3% in August 2026, well below Oregon's 5.1% statewide rate, while metro job postings grew 4.0% year-over-year in Q1 2026 even as Oregon's broader posting activity declined. Regional healthcare and bioscience employment expansion — anchored by St. Charles Health System and Lonza's Bend manufacturing presence — continues absorbing specialized labor against a backdrop of statewide professional and business services contraction.
What it means
Metro-level clinical and manufacturing pay premiums — Clinical Research Associate advertised pay at $119,506 versus $90,956 nationally, Clinical Data Manager at $142,800 versus $123,031 nationally — indicate Bend employers are bidding above national rates to secure scarce credentialed talent rather than relying on local labor supply depth. Lab/R&D vacancy running at 23.2% across top U.S. life sciences markets compounds the build-vs-outsource calculus for Bend-based biotech and device firms weighing CDMO or CRO partnerships against costly in-house hires. Organizations should evaluate whether current CRA and clinical data management compensation reflects genuine scarcity premiums or signals a need to reassess internal clinical operations staffing against outsourced trial execution.
Looking ahead
Worth watching: Oregon Life Sciences Association's move toward shared hiring-plan disclosure among Bend-area biopharma employers, including Thermo Fisher's local operation, could reduce destructive poaching on regulatory and clinical talent if adopted broadly. Watch whether smaller Bend employers gain access to this coordination or remain exposed.
Emerging pressure point: Oregon's manufacturing sector has shed 14,600 jobs statewide over two years even as Bend's own manufacturing-adjacent life sciences employers expand; a widening urban-rural divergence could pull displaced manufacturing talent toward Bend if wages remain competitive. Monitor whether released manufacturing workers from Portland-area WARN filings surface in Bend applicant pools.
Potential inflection point: National biopharma layoffs (BioMarin, Bristol Myers) are concentrated in consolidation and restructuring rather than execution roles, with 64% of surveyed organizations still actively recruiting. Bend employers should watch whether displaced regulatory or CMC talent from these national cuts becomes available locally over the next quarter.
Early indicator: September's BLS metro release (due late September/early October) will confirm whether Bend's unemployment rate holds at 4.3% or continues its gradual climb from 2023 lows. A move toward 5% would narrow the labor-supply advantage Bend currently holds over the statewide rate.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.